Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Dezember 2025 08:30 ET | Quelle: Stemline Therapeutics, Inc.

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early...
24. November 2025 08:30 ET | Quelle: Stemline Therapeutics, Inc.

Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN).BPDCN is a highly aggressive, orphan...
10. Januar 2025 09:00 ET | Quelle: Stemline Therapeutics, Inc.

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312)...
19. Oktober 2023 10:04 ET | Quelle: Menarini

Paralympic Basketball: a new season begins for Volpi Rosse Menarini

FLORENCE, Italy, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Heart, passion, and the determination to overcome challenges. The Volpi Rosse Menarini are once again setting their sights on the hoop as they make...